News

Archive

Resolve Therapeutics receives FDA approval to initiate Phase 2 clinical trial of RSLV-132 in long covid patients Zeotap launches Google Customer Match integration to drive addressability in a post-cookie world iCAD’s ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production Phase Four raises $26m led by New Science Ventures Zeotap launches Predictive Audiences to empower marketers with machine learning
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.